**Distinct inflammation-related proteins associated with T cell immune recovery during chronic HIV-1 infection**

Lin-Yu Wang,a,b Hui-Huang Huang,b, Cheng Zhen,b Si-Yuan Chen,b Bing Song,b Wen-Jing Cao,a Li-Li Shen,b Ming-Ju Zhou,b Xiao-Chang Zhang,d Ruonan Xu,b, Xing Fan,b Ji-Yuan Zhang,b Ming Shi,b, Chao Zhang,b Yan-Mei Jiao,b Jin-Wen Song,a and Fu-Sheng Wang,a,b

**ABSTRACT**

Chronic inflammation and T cell dysregulation persist in individuals infected with human immunodeficiency virus type 1 (HIV-1), even after successful antiretroviral treatment. The mechanism involved is not fully understood. Here, we used Olink proteomics to comprehensively analyze the aberrant inflammation-related proteins (IRPs) in chronic HIV-1-infected individuals, including in 24 treatment-naïve individuals, 33 immunological responders, and 38 immunological non-responders. T cell dysfunction was evaluated as T cell exhaustion, activation, and differentiation using flow cytometry. We identified a cluster of IRPs (cluster 7), including CXCL11, CXCL9, TNF, CXCL10, and IL18, which was closely associated with T cell dysregulation during chronic HIV-1 infection. Interestingly, IRPs in cluster 5, including ST1A1, CASP8, SIRT2, AXIN1, STAMBP, CD40, and IL7, were negatively correlated with the HIV-1 reservoir size. We also identified a combination of CDCP1, CXCL11, CST5, SLAMF1, TRANCE, and CD5, which may be useful for distinguishing immunological responders and immunological non-responders. In conclusion, the distinct inflammatory milieu is closely associated with immune restoration of T cells, and our results provide insight into immune dysregulation during chronic HIV-1 infection.

**ARTICLE HISTORY** Received 13 July 2022; Revised 15 November 2022; Accepted 17 November 2022

**KEYWORDS** HIV-1; Inflammation; HIV-1 reservoir; CXCL9; CXCL10; CXCL11; T cell dysregulation

**Introduction**

Human immunodeficiency virus type 1 (HIV-1) is a major global public health issue, as approximately 38 million individuals are infected with HIV worldwide [1]. The discovery and implementation of efficient, well-tolerated, combinational antiretroviral therapy (ART) has transformed these deadly viral infections into chronic manageable diseases. ART controls the replication of HIV-1, promotes the recovery of CD4 T cells, and improves the survival and quality of life of HIV-1-infected individuals.

Although ART can efficiently control viral replication, approximately 15–30% of HIV-1-infected individuals fail to achieve optimal recovery of CD4 T cell counts despite receiving ART [2]. These patients are referred to as immunological non-responders (INRs) and have a greater risk of serious non-acquired immunodeficiency syndrome (non-AIDS)-related events and mortality [3,4]. However, the precise mechanisms underlying this poor immune recovery are not well-understood. Older age, a low nadir CD4 T cell count, a longer duration of HIV-1 infection, and co-infection with hepatitis C virus are risk factors for suboptimal CD4 T cell count recovery [5–8]. To date, no additional treatment is available for INRs to efficiently restore CD4 T cell counts to normal levels. Therefore, studies are urgently needed to identify potential therapeutic targets for improving immune recovery in these patients. Residual low-grade inflammation persists even after ART treatment, particularly in INRs, and inflammation is associated with poor CD4 T cell recovery [9,10]. Previous studies demonstrated that the levels of sCD14, sCD163, and CXCL10 in the plasma are negatively correlated with CD4 T cell counts [11,12]. Additionally, the levels of sCD14, sCD163, CXCL10, CRP, and IL6 are related to HIV-1 disease progression [13–15]. These studies were performed using limited inflammatory markers; thus, inflammation-related proteins (IRPs) have not been comprehensively described in HIV-1-infected individuals, particularly in INRs.
Chronic HIV-1 infection leads to alterations in T cell subsets with altered maturation and differentiation profiles, in addition to increased levels of immune activation and exhaustion; these immunological scars persist even after ART treatment [16,17]. Higher levels of T cell activation and elevated expression of inflammatory markers, IL6 and sCD14, have been observed in INRs compared to those in immunological responders (IRs) [16]. IL6 and sCD14 are predictive of disease progression and associated with an increased risk of AIDS and death [15]. Additionally, IRPs are central to the homeostatic proliferation and differentiation of CD4 and CD8 T cells in HIV-1 infection [18]. For example, IL7 and IL15 are the principal regulators of CD4 and CD8 T cell homeostasis [19,20]. CXCL10 drives CD4+ T cells towards Th1 cell polarization [21]; the levels of CXCL10 are positively correlated with activation of CD4 and CD8 T cells, regardless of whether the patients have been subjected to ART [22]. However, the association between IRPs and T cell dysregulation is not well-understood.

In this study, we assessed the systemic levels of 92 IRPs in HIV-1-infected individuals and explored the association between IRPs and HIV-1 clinical parameters and T cell differentiation, activation, and exhaustion. We observed significant associations between IRPs in cluster 7 and HIV-1 disease progression. We also identified several IRPs in cluster 5 that were negatively associated with HIV-1 DNA levels in ART-treated individuals. Particularly, we identified a combination of IRPs that can be used to distinguish between INRs and IRs. This comprehensive analysis of chronic inflammation in HIV-1-infected individuals may provide potential targets for improving the prognosis of these patients.

**Materials and methods**

**Patients and samples**

Ninety-five HIV-1-infected individuals were enrolled from the Fifth Medical Center of Chinese PLA General Hospital. Among these patients, 24 were treatment-naïve HIV-1-infected individuals (TNs), 33 were IRs, and 38 were INRs. IRs and INRs were defined as having CD4 T cell counts above and below 350 cells/μL, respectively; individuals in both groups had received ART for more than two years and had plasma HIV-1 viral loads below 80 copies/mL. Twenty healthy controls (HCs) were also included in this study. The exclusion criteria were as follows: pregnancy, AIDS-related diseases, chronic hepatitis B or hepatitis C infection, ongoing immunosuppressive therapy, and moribund status. Plasma samples were collected and stored at −80°C until analysis. Peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll-Hypaque (MD Pacific Biotechnology, Tianjin, China) density gradient centrifugation.

**Flow cytometry**

PBMCs were incubated in Zombie NIR™ Fixable Viability Kit (BioLegend, San Diego, CA, USA) at 4°C for 20 min and then washed. PBMCs were stained with the following human antibodies: CD3-BV650 (clone OKT3), CD27-BV421 (clone M-T271), CD45RA-BV711 (clone HI100), HLA-DR-BV605 (clone L243), CD38-PE-Cy7 (clone HB-7), and PD-1-BV510 (clone EH12.2H7), purchased from BioLegend, and CD8-UV737 (clone SK1) and CCR7-BB700 (clone 3D12), purchased from BD Biosciences (Franklin Lakes, NJ, USA). Events were detected on a BD FACSymphony™ A5 flow cytometer and the data were analyzed using FlowJo software V10 (Tree Star, Ashland, OR, USA).

Dimensionality reduction was performed using the FlowJo plugin UMAP version 2.2. The DownSample version 3.0.0 plugin and concatenation tool were used to visualize multiparametric data from up to 320,000 T cells.

**Proteomic profiling of soluble factors in plasma**

Plasma samples from the cohort were quantified using the Olink multiplex proximity extension assay (PEA) inflammation panel that included 92 IRPs (Olink Bioscience AB, Uppsala, Sweden). PEA uses pairs of oligonucleotide-labeled antibodies to bind to their respective target proteins. When two antibodies are in close proximity, a new polymerase chain reaction (PCR) target sequence is formed through a proximity-dependent DNA polymerization reaction. The resulting sequence was detected and quantified using standard real-time PCR. Olink-generated data were presented as normalized protein expression values, which showed comparable distributions as the log2-transformed protein concentrations. Among our 115 samples, two samples did not pass quality control or deviated from the target populations and thus were excluded from analysis. More than 90% of the values for 18 proteins were below the lower limit of detection; therefore, these proteins were also excluded from further analysis. Seventy-four IRPs from 113 individuals were evaluated in this study. Further information on the Olink assay is available at [http://www.olink.com](http://www.olink.com). Venn diagrams were constructed using an online system ([http://www.ehbio.com/test/venn](http://www.ehbio.com/test/venn)).

**Quantification of HIV-1 DNA and RNA**

Total cellular DNA and RNA were extracted from fresh PBMCs using a Qiagen QIAmp DNA
The distribution of T cell subsets based on CD45RA, CD27, and CCR7 expression cytometric analysis. T cell subsets were identification among HIV-1-infected individuals using We assessed the CD4 and CD8 T cell subset composition of plasma IRPs in HIV-1-infected individuals, four groups were included in this study: 20 HCs, 24 TNs, 33 IRs and 38 INRs (Figure 1). The characteristics of the participants are summarized in Table 1. The INR group was older than the IR group (median, 60.5 vs. 53 years, P = 0.0041). The median CD4 T cell counts were 202.0, 165.0, 292.0, and 768.0 cells/μL in INRs, IRs, TNs, and HCs, respectively. In addition, the baseline CD4 T cell count in the INR group was lower than that in the IR group (median, 60.5 vs. 344.0 cells/μL, P < 0.0001). The duration and regimen of ART did not differ significantly between IRs and INRs.

**Results**

**Characteristics of study participants**

To investigate the characteristics and clinical implications of plasma IRPs in HIV-1-infected individuals, four groups were included in this study: 20 HCs, 24 TNs, 33 IRs and 38 INRs (Figure 1). The characteristics of the participants are summarized in Table 1. The INR group was older than the IR group (median, 43.5 vs. 31 years, P < 0.0001). The median CD4 T cell counts were 196.0, 656.0, 392.0, and 768.0 cells/μL in INRs, IRs, TNs, and HCs, respectively. In addition, the baseline CD4 T cell count in the INR group was lower than that in the IR group (median, 60.5 vs. 344.0 cells/μL, P < 0.0001). The duration and regimen of ART did not differ significantly between IRs and INRs.

**T cell differentiation in HIV-1-infected individuals**

We assessed the CD4 and CD8 T cell subset composition among HIV-1-infected individuals using flow cytometric analysis. T cell subsets were identified based on CD45RA, CD27, and CCR7 expression (Figure S1) [23]. The distribution of T cell subsets and expression of CD8, CD45RA, CD27, and CCR7 in PBMCs from the four groups were visualized using uniform manifold approximation and projection (UMAP) (Figure 2(A), Figure S2). In CD4 T cells, the frequency of transitional memory (T_{TM}) cells decreased (P = 0.0002), but the frequencies of effector memory (T_{EM}) and terminally differentiated (T_{TD}) cells increased in TNs compared to those in HCs (P = 0.0493 and P = 0.0301, respectively) (Figure 2(B)). In CD8 T cells, the frequencies of naïve (T_{N}) and central memory (T_{CM}) cells decreased (P < 0.0001 and P = 0.0464, respectively), whereas the frequencies of T_{TM} and T_{EM} cells increased in TNs compared with those in HCs (P = 0.0001 and P = 0.0177, respectively) (Figure 2(C)). Despite long-term suppression of HIV-1 replication with ART, the distribution of T cell subsets was not fully restored. In INRs, the frequencies of CD4+ T_{EM} (INRs vs. IRs, P = 0.0319; INRs vs. HCs, P = 0.0002), CD8+ T_{TM} (INRs vs. IRs, P = 0.0042; INRs vs. HCs, P = 0.0015), and CD4+ T_{TD} cells (INRs vs. IRs, P = 0.0228; INRs vs. HCs, P = 0.0044) increased, and the frequencies of CD4+ T_{N} (INRs vs. IRs, P < 0.0001; INRs vs. HCs, P < 0.0001) and CD8+ T_{N} cells (INRs vs. IRs, P = 0.0008; INRs vs. HCs, P < 0.0001) decreased compared to those in IRs and HCs (Figure 2(B,C)).

We also evaluated the expression of activation and exhaustion markers on T cells (Figures S2, S3). We found that T cell activation and exhaustion were significantly increased in TNs compared to that in HCs, and ART did not fully restore normal function, particularly in INRs. The frequencies of HLA-DR+, CD38+, and HLA-DR+CD38+ CD4 T cells were higher in INRs than in IRs (P < 0.0001, P = 0.0133, and P = 0.0001 respectively). The frequencies of PD-1+ CD4 (INRs vs. IRs, P < 0.0001; INRs vs. HCs, P < 0.0001 and PD-1+ CD8 (INRs vs. IRs, P = 0.0162; INRs vs. HCs, P = 0.0008) T cells were higher in INRs than in IRs and HCs.

**Soluble IRPs in plasma**

We measured 92 IRPs using the Olink multiplex inflammation panel to investigate the clinical implications of plasma IRPs in HIV-1-infected individuals. The t-SNE analysis based on the expression of IRPs clearly separated HCs, TNs, and HIV-1-infected individuals with ART (IRs plus INRs) (Figure 3(A)). Fifty-two IRPs significantly differed between HIV-1-infected individuals (TNs, IRs, and INRs) and HCs (Figure 3(B)); 41 IRPs were significantly different between TNs and HCs (Table S1), 26 between IRs and HCs (Table S2), and 34 between INRs and HCs (Table S3). In addition, 27 IRPs were significantly different between IRs and TNs (Table S4), 27 between INRs and TNs (Table S5), and 9 between IRs and INRs (Table S6). The differential expression
of these IRPs was visualized using heatmap (Figure 3(C)). The IRP profiles significantly differed between HIV-1-infected individuals and HCs, particularly TNs.

**IRPs correlate with HIV-1 disease progression in TNs**

We evaluated the pairwise correlation between 41 differentially expressed IRPs in TNs and HCs. The IRPs were separated into seven clusters (1–7, from top to bottom) based on their correlation coefficients (Figure 3(A)). Combined with the results shown in Figure 3(C), HIV-1 infection led to decreased levels of IRPs in clusters 1, 4, and 5 and increased levels of IRPs, except for that of CST5, in clusters 6 and 7.

We further evaluated the correlation between IRPs and clinical and immunological variables in TNs; IRPs in cluster 7 were closely related to HIV-1 disease progression (Figure 4(B)). Among the IRPs in cluster 7, CD4+ T cell count was negatively correlated with the levels of CSF1, CXCL11, CXCL23, IL12B, CCL19, and CXCL10. The HIV-1 viral load was positively correlated with CSF1, CXCL11, IL12B, CCL19, IL10, and CXCL9 levels. The frequencies of CD4+ T N and CD8+ T N cells were negatively correlated with the levels of CSF1, CXCL11, CCL23, IL12B, CCL19, TNFRSF9, IL10, CXCL9, TNF, CXCL10, and IL18.

The frequency of HLA-DR+ CD4 T cells was positively correlated with the levels of CSF1, CXCL11, CCL23, IL12B, CCL19, TNFRSF9, IL10, CXCL9, TNF, CXCL10, SLAMF1, IL18R1, and IL18. The frequency of PD-1+ CD8 T cells was positively correlated with the levels of CSF1, CXCL11, CCL23, IL12B, CCL19, TNFRSF9, IL10, CXCL9, TNF, CXCL10, SLAMF1, IL18R1, and IL18. The frequency of PD-1+ CD8 T

**Table 1. Clinical characteristics of study subjects.**

|       | HC        | TN        | IR        | INR       | P value |
|-------|-----------|-----------|-----------|-----------|---------|
| n     | 20        | 24        | 33        | 38        |         |
| Age (years) | 30.0 (27.3–31.8) | 28.0 (26.0–34.0) | 31.0 (27.5–34.5) | 43.5 (36.8–49.3) | <0.0001* |
| Gender, male, n (%) | 15 (75%) | 23 (96%) | 33 (100%) | 35 (92%) | <0.01 b |
| BMI, kg/m² | 22.1 (19.7–25.3) | 21.7 (17.8–24.4) | 23.2 (20.9–25.6) | 22.5 (19.7–24.2) | 0.3290 a |
| CD4 T cell counts (cells/µl) | 768.0 (525.5–925.5) | 392.0 (150.8–652.3) | 656.0 (541.5–807.0) | 196.0 (159.3–238.3) | <0.0001 * |
| CD4 T cell counts at baseline (cells/µl) | NA | NA | 344.0 (201.0–449.5) | 60.5 (17.8–121.3) | <0.0001 c |
| CD8 T cell counts (cells/µl) | 622.0 (513.0–1032.0) | 1043.0 (820.5–1235.0) | 922.0 (631.5–1100.0) | 607.5 (412.4–818.8) | <0.01 * |
| CD4/CD8 ratio | 1.1 (0.9–1.4) | 0.4 (0.2–0.5) | 0.8 (0.6–1.0) | 0.3 (0.2–0.5) | <0.0001 a |
| Time on ART (months) | NA | NA | 48.8 (39.0–63.9) | 45.4 (33.6–54.4) | 0.1794 c |
| ART regimen, n (%) | NA | NA | 31 (94%) | 38 (100%) | 0.1237 b |
| NRTIs + NNRTIs | NA | NA | 2 (6%) | 0 (0%) |         |
| Viral load (copies/ml) | NA | NA | <LDL | <LDL |         |
| Viral load at baseline (copies/ml) | NA | NA | 116,150 (46,175–595,750) | 207,500 (21,525–608,750) | 0.7574 c |

Continuous variables are expressed as the median (interquartile range, IQR) and categorical variables are expressed as the number of cases (%). HC, healthy control; TN, treatment-naïve HIV-1-infected individual; IR, immunological responder; INR, immunological non-responder; BMI, body mass index; ART, antiretroviral therapy; NA, not available; LDL, below lower detection limit; NRTIs, nucleoside reverse transcriptase inhibitors; NNRTIs, non-nucleoside reverse transcriptase inhibitors; Pls, protease inhibitors; aKruskal-Wallis test; bχ² test; cMann-Whitney U test.
cells was positively correlated with the levels of IFN-γ, IL15RA, TNFRSF9, and IL18R1.

We also performed GO analysis of the 17 IRPs in cluster 7 and found that the most represented categories were “inflammatory response,” “positive regulation of NIK/NF-kappaB signalling,” “chemokine-mediated signalling pathway,” “cellular response to lipopolysaccharide,” and “positive regulation of interferon-gamma production,” suggesting that these biological processes are altered during HIV-1 infection (Table S7).

**IRPs correlate with immune recovery in patients on ART**

We found that the levels of CXCL11, CXCL9, TNF, CXCL10, SLAMF1, CST7, CDCP1, and IL18 in cluster 7 remained abnormal after ART (Figure S4). Analysis of the correlation between IRPs and clinical and immunological variables in patients on ART revealed that the abnormal IRPs in cluster 7 were closely related to clinical parameters (Figure 5). In patients on ART, CD4 T cell counts and the CD4/CD8 ratio were negatively correlated with CXCL11 levels. The frequencies of CD4+ TN and CD8+ TN cells were negatively correlated with levels of CXCL11 and IL18, the frequency of HLA-DR+ CD38+ CD8 T cells was positively correlated with the level of CXCL9, and the frequency of PD-1+ CD4 T cells was positively correlated with levels of SLAMF1 and IL18. Furthermore, we measured HIV-1 DNA and cell-associated unspliced RNA in patients on ART. HIV-1 DNA levels were positively correlated with HIV-1 RNA levels in ART-treated patients (IRs plus INRs) \((r = 0.2556, P = 0.0314)\) and IRs \((r = 0.4206, P = 0.0148)\), whereas no correlation was observed in INRs (Figure S5). A significant negative association was detected between HIV-1 DNA and the levels of ST1A1, CASP8, SIRT2, AXIN1, STAMB, CD40, and IL7 in cluster 5 (Figure 5). CDCP1 levels were positively correlated with HIV-1 DNA levels.
RNA levels (Figure 5). Interestingly, evaluation of the correlation between IRPs and clinical and immunological variables in IRs and INRs showed that most IRPs in cluster 5, including CXCL5, ST1A1, CASP8, SIRT2, AXIN1, STAMBP, and IL7, were negatively correlated with HIV-1 DNA levels in IRs but not with those in INRs (Figure S6A, S6B).

To identify IRPs that could distinguish INRs from IRs, nine significantly differentially expressed proteins between IRs and INRs, including CDCP1, OPG, CD5, uPA, CXCL11, CST5, SLAMF1, TRANCE, and Flt3L (Table S6), were examined using multivariable linear regression. Six IRPs, including CDCP1, CXCL11, CST5, SLAMF1, TRANCE, and CD5, were significant factors (Table S8). Receiver operating characteristic curve analysis indicated that these six proteins had a differentiated value of 95.06% ($P < 0.0001$) between IRs and INRs, and the model was verified by leave-one-out cross-validation (Figure 6(A)). Among the six IRPs, the levels of CDCP1, CXCL11, CST5, and SLAMF1 were higher in INRs than in IRs and the levels of TRANCE and CD5 were lower in INRs than in IRs (Figure 6(B)).

To identify IRPs that could distinguish INRs from IRs, nine significantly differentially expressed proteins between IRs and INRs, including CDCP1, OPG, CD5, uPA, CXCL11, CST5, SLAMF1, TRANCE, and Flt3L (Table S6), were examined using multivariable linear regression. Six IRPs, including CDCP1, CXCL11, CST5, SLAMF1, TRANCE, and CD5, were significant factors (Table S8). Receiver operating characteristic curve analysis indicated that these six proteins had a differentiated value of 95.06% ($P < 0.0001$) between IRs and INRs, and the model was verified by leave-one-out cross-validation (Figure 6(A)). Among the six IRPs, the levels of CDCP1, CXCL11, CST5, and SLAMF1 were higher in INRs than in IRs and the levels of TRANCE and CD5 were lower in INRs than in IRs (Figure 6(B)). We also analyzed the expression of these six IRPs among TNs, which were categorized into two groups based on low and high CD4 T cell counts and viral loads, respectively. These IRPs did not differ between the two groups. (Figure S7).

Furthermore, we performed GO analysis of 26 differentially expressed IRPs between IRs and HCs and 34 differentially expressed IRPs between INRs and HCs. Among the top 10 biological processes, the "cellular response to LPS" was specific to INRs (Tables S79 and S10). Consistently, a previous study showed that the plasma levels of lipopolysaccharide (LPS) are higher in INRs than in IRs [24]. LPS is the major component of the gram-negative bacterial outer membrane and is highly antigenic. LPS is responsible for chronic immune activation and inflammation during HIV-1 infection [25].

Discussion

Despite the successful control of HIV-1 viremia achieved using ART, HIV-1-infected individuals, particularly the INR population, still experience a higher incidence of non-AIDS-related events, which is partially attributed to residual chronic inflammation and immune activation. In this study, we systematically analyzed IRPs in HIV-1-infected individuals with various disease statuses and analyzed the association of these IRPs with T cell dysfunction and HIV-1 disease progression. We found that HIV-1 infection altered T cell differentiation, activation, and exhaustion. Abnormal expression of IRPs is closely related to HIV-1 disease progression and T cell dysfunction (Figure 7).

In our study, INRs were older and had lower baseline CD4 T cell counts compared to those of IRs, which is in consistent with previous studies showing that the older age and low baseline CD4 T cell counts are associated with poor immune recovery in HIV-1-infected individuals [5,6,8]. Previous studies showed that TN cells decreased with advanced age [26,27].
and exhibited proliferation and effector differentiation defects, further contributing to T cell dysfunction and activation among older patients [27,28].

HIV-1 infection-induced T cell dysfunction is not fully recovered by ART treatment, particularly in INRs. Consistent with the results of previous studies [29–31], we observed decreased frequencies of CD4+ Tology and CD8+ Tcells, as well as increased frequencies of CD4+ TEM and CD8+ TEM cells, in INRs compared to those in IRs and HCs. Decreased frequencies of Tcells may be related to reduced thymic output and the differentiation of T cells into memory and effector T cells [2,32]. TEM cells can migrate to inflamed peripheral tissues and exert effector functions; however, the increased frequencies of TEM cells may be related to over-activation and accelerated exhaustion in INRs.

**Figure 4.** Association between inflammation-related proteins with clinical and immunological variables in treatment-naïve HIV-1-infected individuals. Differentially expressed IRPs between treatment-naïve individuals (TNs) and healthy controls (HCs) were determined. (A) Correlation among inflammation-related proteins (IRPs) is displayed using Spearman’s correlation matrix. Based on the correlation between the IRPs, these proteins were separated into seven clusters (1–7, from top to bottom). The clusters are highlighted in heatmap black boxes. (B) Heatmap showing Spearman correlations between differentially expressed proteins and clinical and immunological variables. Red and blue indicate positive and negative associations, respectively. *P < 0.05, **P < 0.01, ***P < 0.001.
In addition, compared to that in HCs and IRs, T cell activation and exhaustion were higher in INRs [16,29]. The mechanisms underlying immune activation are complex. Translocation of intestinal microbes into the bloodstream is one cause of systemic immune activation during HIV-1 infection [33]. LPS, an indicator of microbial translocation, is significantly increased during HIV-1 infection and is higher in INRs than in IRs [24,34,35]. In addition, regulatory T cells play important roles in inhibiting T cell activation and proliferation. However, regulatory T cells are decreased in HIV-1-infected individuals and may lead to abnormal immune activation [36]. Persistent activation of T cells may also lead to T cell exhaustion. Inflammation is a hallmark of HIV-1 infection, but the association between IRPs and T cell dysregulation is not fully understood. Therefore, we evaluated the levels of 92 IRPs and found that CXCL11, CXCL9, TNF, CXCL10, SLAMF1, and IL18 in cluster 7 were closely associated with T cell differentiation, T cell activation and exhaustion, and disease progression in TNs. Some differentially expressed IRPs between

Figure 5. Associations between inflammation-related proteins with clinical and immunological variables in patients on ART. Differentially expressed inflammation-related proteins (IRPs) between antiretroviral therapy (ART)-treated HIV-1-infected individuals and healthy controls (HCs) were determined. The heatmap shows the Spearman correlations between the differentially expressed proteins and clinical and immunological variables. Red and blue indicate positive and negative associations, respectively. *P < 0.05, **P < 0.01, ***P < 0.001.

Figure 6. Inflammation-related proteins for differentiating immunological responders and immunological non-responders in plasma. (A) Panel of six differentially expressed inflammation-related proteins (IRPs), including CDCP-1, CXCL11, CST5, SLAMF1, TRANCE, and CDS, was used to distinguish immunological non-responders (INRs) from immunological responders (IRs). (B) Expression levels of CDCP-1, CXCL11, CST5, SLAMF1, TRANCE, and CDS in IRs and INRs. Data are expressed as the median (interquartile range, IQR). Statistical significance between two groups was determined by non-parametric, unpaired Mann–Whitney U test. AUC, area under the curve. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
HIV-1 infection leads to the upregulation of a cluster of inflammation-related proteins (IRPs) (cluster 7), including CXCL11, CXCL9, TNF, CXCL10, IL18, CDCP1, and SLAMF1. These IRPs remained abnormal despite antiretroviral therapy (ART), particularly in immunological non-responders (INRs). Importantly, these IRPs in cluster 7 were closely associated with T cell differentiation, activation, and exhaustion.

HCs and TNs remained abnormal after ART, specifically the proteins in cluster 7. Particularly, CXCL9, CXCL10, and CXCL11 in cluster 7 were closely associated with disease progression and immune disorders, irrespective of whether the patients had been treated with ART. CXCL9, CXCL10, and CXCL11 are IFN-γ-induced chemokines secreted by monocytes, endothelial cells, and fibroblasts and interact with cell surface CXCR3 [37]. The interaction of these ligands with CXCR3 affects both the migration of T cells into inflamed regions and their polarization into effector T cells [38]. In addition, CXCL9, CXCL10, and CXCL11 play important roles in regulating the differentiation of T_N cells to Th1 cells and in immune activation [39]. Th1 cells produce IFN-γ, TNF, and IL2 and promote immune reactivity by stimulating cytotoxic T cells, natural killer cells, natural killer T cells, and macrophages [40]. IL18, secreted primarily by dendritic cells and macrophages, may affect the production of CXCL9, CXCL10, and CXCL11 by driving IFN-γ secretion [41]. A previous study demonstrated that CXCL9, CXCL10, and CXCL11 levels can predict HIV-1 disease progression during primary HIV-1 infection [42]. Therefore, blocking the CXCL9, CXCL10, and CXCL11/CXCR3 axes shows potential as an approach for decreasing immune activation and exhaustion. Multivariate regression analysis showed that a combination of CDCP1, CXCL11, CST5, SLAMF1, TRANCE, and CD5 could be used to distinguish INRs from IRs. CDCP1, a ligand for CD6 expressed on T cells, acts as a co-stimulatory receptor in the immunological synapse and has been proposed as a molecular target for treating malignancy [43]. As previously described, CXCL11 is associated with HIV-1 disease progression. CST5, which encodes an inhibitor of several cysteine proteases of the cathepsin family, is a candidate tumour suppressor gene [44].

CST5 and TRANCE can suppress the activation and resorption of osteoclasts [45,46], which may be associated with HIV-1-related bone disease. SLAMF1, also known as CD150, plays an important role in immunosuppression of HIV-1 infection. Patients with acute HIV-1 infection show decreased CD150 expression on T cells, which correlates with impaired Th1 cell-mediated responses [47,48]. CD5 has been widely reported to be involved in modulating signalling through antigen receptors in both T and B cells. We found that CD5 levels were lower in INRs than in IRs, which may reflect a low capacity to respond to immune activation.

Persistence of the HIV-1 reservoir is a major obstacle to eradicating HIV-1 and is the underlying cause of immune activation and inflammation [49]. We found that ST1A1, CASP8, SIRT2, AXIN1, STAMBP, CD40, and IL7 in cluster 5 were negatively associated with HIV-1 DNA. ST1A1, a cytosolic sulphotransferase, regulates HIV-1 reverse transcription in monocyte-derived macrophages [50]. CASP8, a caspase protein, is the upstream protease involved in the activation cascade responsible for death receptor-induced cell death [51]. SIRT2 is a member of the sirtuin family, which is comprised of NAD (+)-dependent deacetylases involved in several cellular processes. SIRT2 can regulate NF-kB signalling via deacetylase p65 [52], which may affect HIV-1 latency [53]. AXIN1, a regulator of WNT signalling, plays a negative role in HIV-1 transcription through the WNT signalling pathway under normal cell culture conditions [54]. STAMBP, also known as AMSH, inhibits the release of inflammatory factors by negatively regulating NLRP3 inflammasome destabilization [55]. A previous study reported that structural destabilization of STAMBP leads to loss of function during HIV-1 budding [56]. CD40, also called TNFRSF5, interacts with its ligand CD40L, which contributes to the immunological control of HIV-1 replication by inducing HIV-suppressive chemokines and supporting the production of anti-HIV antibodies and cytotoxic T cells [57]. IL7 is crucial for T cell survival and homeostatic maintenance of peripheral T cells. IL7 significantly enhances HIV-1 proviral reactivation [58]. Although negative correlations were observed between these proteins and HIV-1 DNA, their causal relationship requires further investigation. In addition, we found that ST1A1, CASP8, SIRT2, AXIN1, STAMBP, CD40, and IL7 in cluster 5 were negatively associated with HIV-1 DNA in IRs but not in INRs. HIV-1 DNA is relatively stable in IRs with an optimal immune status. However, INRs are susceptible to opportunistic infections. The weakened immune surveillance of HIV-1 upon reactivation coupled with infection-induced immune activation may impact the stability of the HIV-1 reservoir in INRs. Moreover, compared...
to IRs, INRs have higher levels of HIV-1 DNA and RNA [59,60].

There were several limitations to this study. First, the mechanisms how IRPs affect T cell immune recovery requires further analysis, as the associations do not necessarily indicate causality. Second, the PCR-based assay in our study overestimated the HIV-1 reservoir size, as it cannot distinguish between replication competent and defective proviral genomes. Finally, because of the lack of samples, we could not assess the functions of T cell subsets, including cytotoxicity and cytokine-secreting abilities. Future studies are needed to reveal the association of aberrant IRPs with T cell functions.

In conclusion, inflammation and T cell dysregulation persist in ART-treated HIV-1-infected individuals. Some IRPs in cluster 7, such as CXCL11, CXCL9, TNF, CXCL10, and IL18, are closely associated with HIV-1 disease progression and immune disorders, irrespective of whether patients received ART treatment. These results may facilitate identification of an effective immune intervention strategy.

Study approval
This study was approved by the ethics committee of the Fifth Medical Center of Chinese PLA General Hospital (ky-2021–7–6–1), and written informed consent was obtained from all study participants in accordance with the Declaration of Helsinki.

Acknowledgements
The authors thank Rui-Chuang Yang, Chun-Bao Zhou, and Jin-Hong Yuan for their excellent technical support with flow cytometry analysis, and we appreciate the efforts of all our team technicians for their hard work throughout this study. JWS and FSW conceived and designed the study. LYW collected clinical samples and performed the experiments with assistance from HHH, BS, WJC, LLS, and MJZ. HHH and BS collected clinical information. LYW, CZ, SYC, and XCZ analyzed data. JWS, FSW, and LYW interpreted data. JWS, FSW, and MJZ. HHH and BS collected clinical information. The authors thank Rui-Chuang Yang, Chun-Bao Zhou, and Jin-Hong Yuan for their excellent technical support with flow cytometry analysis, and we appreciate the efforts of all our team technicians for their hard work throughout this study. JWS and FSW conceived and designed the study. LYW collected clinical samples and performed the experiments with assistance from HHH, BS, WJC, LLS, and MJZ. HHH and BS collected clinical information. LYW, CZ, SYC, and XCZ analyzed data. JWS, FSW, and LYW interpreted data. JWS, FSW, and MJZ. HHH and BS collected clinical information. The order of the co-first authors was assigned based on the relative contributions of the individuals. All authors read and approved the final version before submission.

Disclosure statement
No potential conflict of interest was reported by the author(s).

Funding
This work was supported by grants from the National Natural Science Foundation of China [grant numbers 82101837, 81901617], the Natural Science and Technology Major Project [grant number 2018ZX10302104-002-001], the Beijing Natural Science Foundation [grant number 7222171].

Data availability statement
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

ORCID
Jin-Wen Song @ http://orcid.org/0000-0002-8582-8012

References
[1] Hayes RJ, Donnell D, Floyd S, et al. Effect of universal testing and treatment on HIV incidence – HPTN 071 (PopART). N Engl J Med. 2019 Jul 18;381(3):207–218. DOI:10.1056/NEJMoa1814556.
[2] Yang X, Su B, Zhang X, et al. Incomplete immune reconstitution in HIV/AIDS patients on antiretroviral therapy: challenges of immunological non-responders. J Leukoc Biol. 2020 Apr;107(4):597–612. DOI:10.1002/JLB.4MR1019-189R.
[3] Farahani M, Mulinder H, Farahani A, et al. Prevalence and distribution of non-AIDS causes of death among HIV-infected individuals receiving antiretroviral therapy: a systematic review and meta-analysis. Int J STD AIDS. 2017 Jun;28(7):636–650. DOI:10.1177/0956462416632428.
[4] Weber R, Ruppik M, Rickenbach M, et al. Decreasing mortality and changing patterns of causes of death in the Swiss HIV cohort study. HIV Med. 2013 Apr;14 (4):195–207. DOI:10.1111/j.1468-1293.2012.01051.x.
[5] Ahn MY, Jiamsakul A, Khusuwan S, et al. The influence of age-associated comorbidities on responses to combination antiretroviral therapy in older people living with HIV. J Int AIDS Soc. 2019 Feb;22(2):e25228. DOI:10.1002/JLB.4MR1019-189R.
[6] Roul H, Mary-Krause M, Ghosn J, et al. CD4+ cell count recovery after combined antiretroviral therapy in the modern combined antiretroviral therapy era. AIDS. 2018 Nov 13;32(17):2605–2614. DOI:10.1097/QAD.0000000000002010.
[7] Marcus JL, Leyden WA, Chao CR, et al. Differences in response to antiretroviral therapy by Sex and hepatitis C infection status. AIDS Patient Care STDS. 2015 Jul;29(7):370–8. DOI:10.1089/apc.2015.0040.
[8] Liu J, Wang L, Hou Y, et al. Immune restoration in HIV-1-infected patients after 12 years of antiretroviral therapy: a real-world observational study. Emerg Microbes Infect. 2020 Dec;9(1):2550–2561. DOI:10.1097/QAD.0000000000002928.
[9] Tenorio AR, Zheng Y, Bosch RJ, et al. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbidity events during suppressive antiretroviral treatment. J Infect Dis. 2014 Oct;210(8):1248–59. DOI:10.1093/jid/jiu254.
[10] Angelidou K, Hunt PW, Landay AL, et al. Changes in inflammation but not T-cell activation precede Non-AIDS-defining events in a case-control study of patients on long-term antiretroviral therapy. J Infect Dis. 2018 Jun;20;218(2):239–248. DOI:10.1093/infdis/jix666.
[11] Liang H, Duan Z, Li D, et al. Higher levels of circulating monocyte-platelet aggregates are correlated with viremia and increased sCD163 levels in HIV-1 infection. Cell Mol Immunol. 2015 Jul;12(4):435–43. DOI: 10.1038/cmi.2014.66.

[12] Liovat AS, Rey-Cuille MA, Lecouroy C, et al. Acute plasma biomarkers of T cell activation set-point levels and of disease progression in HIV-1 infection. PLoS One. 2012;7(10):e46143. DOI: 10.1371/journal.pone.0046143.

[13] Knudsen TB, Ertner G, Petersen J, et al. Plasma soluble CD163 level independently predicts All-cause mortality in HIV-1-infected individuals. J Infect Dis. 2016 Oct 15;214(8):1198–204. DOI: 10.1093/infdis/jiw263.

[14] Sandler NG, Wand H, Roque A, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2011 Mar 15;203(6):780–90. DOI: 10.1093/infdis/jiq118.

[15] Kuller LH, Tracy R, Beloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008 Oct 21;5(10):e203. DOI: 10.1371/journal.pmed.0052020.

[16] Lederman MM, Calabrese L, Funderburg NT, et al. Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J Infect Dis. 2011 Oct 15;204(8):1217–26. DOI: 10.1093/infdis/jir507.

[17] Deeks SG, Tracy R, Douek DC. Systemic effects of inflammation on health during chronic HIV infection. Immunity. 2013 Oct 17;39(4):633–45. DOI: 10.1016/j.immuni.2013.10.001.

[18] Freeman MI, Shive CL, Nguyen TP, et al. Cytokines and T-cell homeostasis in HIV infection. J Infect Dis. 2016 Oct 1;214(Suppl. 2):S31–7. DOI: 10.1093/infdis/jiw287.

[19] Schluns KS, Kieper WC, Jameson SC, et al. Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo. Nat Immunol. 2000 Nov;1(5):426–32. DOI: 10.1038/80686.

[20] Verbit KC, Klonowski KD. Functions of IL-15 in anti-viral immunity: multiplicity and variety. Cytokine. 2012 Sep;59(3):467–78. DOI: 10.1016/j.cyto.2012.05.020.

[21] Wildbaum G, Netzer N, Karin N. Plasmid DNA encoding IFN-gamma-inducible protein 10 redirects antigen-specific T cell polarization and suppresses experimental autoimmune encephalomyelitis. J Immunol. 2002 Jun 1;168(11):5885–92. DOI: 10.4049/jimmunol.168.11.5885.

[22] Noel N, Boufassa F, Lecouroy C, et al. Elevated IP10 levels are associated with immune activation and low CD4(+) T-cell counts in HIV controller patients. AIDS. 2014 Feb 20;28(4):467–76. DOI: 10.1097/QAD.0000000000000174.

[23] Song JW, Zhang C, Fan X, et al. Immunological and inflammatory profiles in mild and severe cases of COVID-19. Nat Commun. 2020 Jul 8;11(1):3410. DOI: 10.1038/s41467-020-17240-2.

[24] Luo Z, Heath SL, Li M, et al. Variation in blood microbial lipopolysaccharide (LPS) contributes to immune reconstitution in response to suppressive antiretroviral therapy in HIV. EBioMedicine. 2022 Jun;80:104037.

[25] Vassallo M, Mercie P, Cottalorda J, et al. The role of lipopolysaccharide as a marker of immune activation in HIV-1 infected patients: a systematic literature review. Virol J. 2012 Aug 27;9:174.

[26] Saule P, Trauet J, Dutriez V, et al. Accumulation of memory T cells from childhood to old age: central and effector memory cells in CD4(+) versus effector memory and terminally differentiated memory cells in CD8(+) compartment. Mech Ageing Dev. 2006 Mar;127(3):274–81. DOI: 10.1016/j.mad.2005.11.001.

[27] Kumar BV, Connors TJ, Farber DL. Human T Cell Development, Localization, And function throughout life. Immunology. 2018 Feb 20;48(2):202–213. DOI: 10.1016/j.immuni.2018.01.007.

[28] Wang XM, Zhang JY, Xing X, et al. Global transcriptomic characterization of T cells in individuals with chronic HIV-1 infection. Cell Discov. 2022 Mar 28;8(1):29. DOI: 10.1038/s41421-021-00367-x.

[29] Shive CL, Freeman ML, Younes SA, et al. Markers of T cell exhaustion and senescence and their relationship to plasma TGF-beta levels in treated HIV+ immune Non-responders. Front Immunol. 2021;12:638010.

[30] Carvalho-Silva WHV, Andrade-Santos JL, Souto FO, et al. Immunological recovery failure in cART-treated HIV-positive patients is associated with reduced thymic output and RTE CD4+ T cell death by pyroptosis. J Leukoc Biol. 2020 Jan;107(1):85–94. DOI: 10.1002/jlb.A40919-235R.

[31] Pino M, Pereira Ribeiro S, Pagliuzza A, et al. Increased homeostatic cytokines and stability of HIV-infected memory CD4 T-cells identify individuals with suboptimal CD4 T-cell recovery on-ART. PLoS Pathog. 2021 Aug;17(8):e1009825. DOI: 10.1371/journal.ppat.1009825.

[32] Li T, Wu N, Dai Y, et al. Reduced thymic output is a major mechanism of immune reconstitution failure in HIV-infected patients after long-term antiretroviral therapy. Clin Infect Dis. 2011 Nov;53(9):944–51. DOI: 10.1093/cid/cir552.

[33] Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006 Dec;12(12):1365–71. DOI: 10.1038/nm1511.

[34] Marchetti G, Tincati C, Silvestri G. Microbial translocation in the pathogenesis of HIV infection and AIDS. Clin Microbiol Rev. 2013 Jan;26(1):2–18. DOI: 10.1128/CMR.00050-12.

[35] Caradonna L, Amati L, Magrone T, et al. Enteric bacteria, lipopolysaccharides and related cytokines in inflammatory bowel disease: biological and clinical significance. J Endotoxin Res. 2000 Jun;6(3):205–14.

[36] Lv T, Cao W, Li T. HIV-Related Immune activation and inflammation: current understanding and strategies. J Immunol Res. 2021;2021:7316456.

[37] Flier J, Boorsma DM, Bruynzeel DP, et al. The CXCR3 activating chemokines IP-10. Mig, and IP-9, are expressed in allergic but not in irritant patch test reactions. J Invest Dermatol. 1999 Oct;113(4):574–8.

[38] Hickman HD, Reynoso GV, Nguidjikama BF, et al. CXCR3 chemokine receptor enables local CD8(+ ) T cell migration for the destruction of virus-infected cells. Immunity. 2015 Mar 17;42(3):524–37. DOI: 10.1016/j.immuni.2015.02.009.

[39] Tokunaga R, Zhang W, Naseem M, et al. CXCL9, Cxcr3 axis for immune activation – a target for novel cancer therapy. Cancer Treat Rev. 2018 Feb;63:40–47.

[40] Kagi D, Ledermann B, Burki K, et al. Cytotoxicity mediated by T cells and natural killer cells is greatly
impaired in perforin-deficient mice. Nature. 1994 May 5;369(6473):31–7.

[41] Dinarello CA. IL-18: A TH1-inducing, proinflammatory cytokine and new member of the IL-1 family. J Allergy Clin Immunol. 1999 Jan;103(1):11–24.

[42] Yin X, Wang Z, Wu T, et al. The combination of CXCL9, CXCL10, and CXCL11 levels during primary HIV infection predicts HIV disease progression. J Transl Med. 2019 Dec 13;17(1):417.

[43] Kollmorgen G, Niederfellner G, Lifke A, et al. Antibody mediated CDCP1 degradation as mode of action for cancer targeted therapy. Mol Oncol. 2013 Dec;7(6):1142–51. DOI: 10.1016/j.molonc.2013.08.009.

[44] Alvarez-Diaz S, Valle N, Garcia JM, et al. Cystatin D is a candidate tumor suppressor gene induced by vitamin D in human colon cancer cells. J Clin Invest. 2009 Aug;119(8):2343–58. DOI:10.1172/JCI37205.

[45] Wang F, Zhang C, Ge W, et al. Up-regulated CST5 inhibits bone resorption and activation of osteoclasts in rat models of osteoporosis via suppression of the NF-kappaB pathway. J Cell Mol Med. 2019 Oct;23 (10):6744–6754. DOI:10.1111/jcem.14552.

[46] Titanji K. Beyond antibodies: B cells and the OPG/RANK-RANKL pathway in health, Non-HIV disease and HIV-induced bone loss. Front Immunol. 2017;8:1851. DOI:10.3389/fimmu.2017.01851.

[47] Siderenko SP, Clark EA. The dual-function CD150 receptor subfamily: the viral attraction. Nat Immunol. 2003 Jan;4(1):19–24. DOI:10.1038/nm0103-19.

[48] Seromeni L, Fusi ML, Varchetta S, et al. Altered signaling lymphocytic activation molecule (SLAM) expression in HIV infection and direction of HIV-specific responses via SLAM triggering. Clin Immunol. 1999 Sep;92(3):276–84. DOI:10.1006/clim.1999.4747.

[49] Massanella M, Fromentin R, Chomont N. Residual inflammation and viral reservoirs: alliance against an HIV cure. Curr Opin HIV AIDS. 2016 Mar;11 (2):234–41. DOI:10.1097/COH.0000000000000230.

[50] Swann J, Murry J, Young JA. Cytosolic sulfotransferase 1A1 regulates HIV-1 minus-strand DNA elongation in primary human monocyte-derived macrophages. Virol J. 2016 Feb 24;13:30.

[51] Deegan S, Saveljeva S, Logue SE, et al. Deficiency in the mitochondrial apoptotic pathway reveals the toxic potential of autophagy under ER stress conditions. Autophagy. 2014;10(11):1921–36. DOI:10.4161/15548627.2014.981790.

[52] Rothgiesser KM, Erenser S, Waibel S, et al. SIRT2 regulates NF-kappaB dependent gene expression through deacetylation of p65 Lys310. J Cell Sci. 2010 Dec 15;123(24):4251–8. DOI:10.1242/jcs.073783.

[53] Chan JK, Greene WC. NF-kappaB/Rel: agonist and antagonist roles in HIV-1 latency. Curr Opin HIV AIDS. 2011 Jan;6(1):12–8. DOI:10.1097/COH.0b013e32834124fd.

[54] Kameoka M, Kameoka Y, Utachee P, et al. Short communication: RNA interference directed against Axin1 upregulates human immunodeficiency virus type 1 gene expression by activating the Wnt signaling pathway in HeLa-derived J111 cells. AIDS Res Hum Retroviruses. 2009 Oct;25(10):1005–11. DOI:10.1089/aid.2008.0284.

[55] Bednash JS, Johns F, Patel N, et al. The deubiquitinase STAMBP modulates cytokine secretion through the NLRP3 inflammasome. Cell Signal. 2021 Mar;79:109859.

[56] Zamborlini A, Usami Y, Radoshitzky SR, et al. Release of autoinhibition converts ESCRT-III components into potent inhibitors of HIV-1 budding. Proc Natl Acad Sci U S A. 2006 Dec 12;103(50):19140–5. DOI:10.1073/pnas.0603788103.

[57] Kornbluth RS. The emerging role of CD40 ligand in HIV infection. J Leukoc Biol. 2000 Sep;68(3):373–82. DOI:10.1189/jlb.68.3.373.

[58] Wang FX, Xu Y, Sullivan J, et al. IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest. 2005 Jan;115(1):128–37. DOI:10.1172/JCI200522574.

[59] Zhang LX, Song JW, Zhang C, et al. Dynamics of HIV reservoir decay and naive CD4 T-cell recovery between immune non-responders and complete responders on long-term antiretroviral treatment. Clin Immunol. 2021 Aug;229:108773.

[60] Real F, Capron C, Sennepin A, et al. Platelets from HIV-infected individuals on antiretroviral drug therapy with poor CD4(+) T cell recovery can harbor replication-competent HIV despite viral suppression. Sci Transl Med. 2020 Mar 18;12:535. DOI:10.1126/scitranslmed.aat6263.